Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              An Interim Analysis of Efficacy and Safety Data in Black and Hispanic Patients With Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial

              Author:Bernitsas, Evanthia   Reder, Anthony   Chinea, Angel   Herrman, Craig   O'Brien, Barbara   Sater, Richard   Amezcua, Lilyana   Williams, Mitzi   Wu, Gregory   Vartanian, Timothy   Pei, Jinglan   Acosta, Juan   Monson, Nancy   

              Session Name:S31: MS Clinical Decision Making and Special Populations  

              Topic:MS and Inflammatory Disease  

              Program Number:S31.006  

              Author Institution:Wayne State University School of Medicine, Detroit, MI  University of Chicago Medicine, Oak Park, IL  San Juan MS Center, San Juan, PR  JWM Neurology, Indianapolis, IN  Baptist Memorial Hospital-Collierville, Collierville, TN  Cone Health Medical Group, Greensboro, NC  Keck School of Medicine, University of Southern California, Los Angeles, CA  Joi Life Wellness MS Center, Smyrna, GA  Washington University in St Louis, St Louis, MO  Brain and Mind Research Institute, Weill Cornell Medicine, Cornell University, New York, NY  Genentech, Inc., South San Francisco, CA  University of Texas Southwestern, Dallas, TX  

              Effect of RIPK1 Inhibitor, SAR443820, on Serum Neurofilament Light Levels in Patients with Multiple Sclerosis: A Phase 2 Trial Design

              Author:Montalban, Xavier   Kuhle, Jens   Fox, Robert   Vartanian, Timothy   Horakova, Dana   Filippi, Massimo   Roos, Ernest   Wallstroem, Erik   Atassi, Nazem   

              Session Name:P6: MS Clinical Trials  

              Topic:MS and Inflammatory Disease  

              Program Number:P6.011  

              Author Institution:Multiple Sclerosis Centre of Catalonia, Department of Neurology–Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain  Department of Neurology, University Hospital and University of Basel, Basel, Switzerland  Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH  Brain and Mind Research Institute, Weill Cornell Medicine, Cornell University, New York, NY  Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic  Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy  Sanofi, Bridgewater, NJ  Sanofi, Cambridge, MA